XtalPi
Business Services · China · 1K - 5K Employees
View Company Info for Free
Overview
Headquarters
Second Phase of the International 3/f Bi...Phone Number
+86 75581901777Website
www.xtalpi.comRevenue
$117.7 MillionStock Symbol
2228.HKIndustry
ZI Rank: 2
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
2
1
1
2
3
2
About XtalPi
Founded in 2014, XtalPi is a biotech firm that uses artificial intelligence and computing to accelerate the development of new drugs. The firm uses algorithms to predict the crystalized form a drug will take. The data enables XtalPi to work with other pharmaceutical companies to develop new drugs and create new patents.XtalPi is located in ChinaExplore more
XtalPi Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is XtalPi your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if XtalPi has recently received funding, and reach out quickly before it becomes old news!
Click to see if XtalPi had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at XtalPi
Product Launch: Get notified when XtalPi launches new products
Earning: See what the market has to say on XtalPi recently announced quarterly report
XtalPi, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if XtalPi is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once XtalPi has new funding data
Website visits: Recent activity has been detected on your website
Recommended Actions
Reach out to Masked Content who joined XtalPi as Masked Content
Find 3 more new buyers
Company Profile Activity
Activity Insights
XtalPi is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
XtalPi is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about XtalPi.
XtalPi financials insights
Gather financial insights about XtalPi, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2015
Series A
$5M
2020
Series C
$318.8M
2021
Series B
$61M
Series D
$400M
XtalPi Tech Stack
A closer look at the technologies used by XtalPi
Most Recent Scoops
Project
XtalPi has launched a Physical AI system that stably produces more than 50,000 reaction yield data points and 300,000 processed data points each month, with more than 500,000 complete real experimental records accumulated to date. Approximately 80% of these records are failed negative samples, which are critical for training reliable models, identifying unproductive paths, and calibrating prediction boundaries.
Research & Development, Machine Learning, Artificial Intelligence
Project
XtalPi has developed a molecular glue platform that has accumulated more than 40 novel CRBN binding cores, 150,000 molecular building blocks, and a virtual molecular glue library of approximately 2.58 million molecules, with automated synthesis and testing of approximately 600 to 1,000 compounds per week. The platform has generated hit compounds against multiple targets in autoimmune disease, with some programs achieving picomolar target protein degradation in approximately one quarter.
Research & Development, Medical Research, Pharmaceuticals
Project
XtalPi has developed a peptide platform that addresses traditional bottlenecks in stability, cell membrane penetration, and oral bioavailability, incorporating a database of more than 5,000 non-standard amino acids and AI models for designing complex peptides including cyclic peptides. A brain discovery program has entered in vivo animal testing with PCC expected in H1 2027, and an oral cyclic peptide program identified hit compounds approximately two months after launch with PCC expected by mid-2027.
Research & Development, Medical Research, Pharmaceuticals, Artificial Intelligence
Project
XtalPi has built a drug pipeline comprising three programs currently in clinical trials, more than 10 programs at IND-approved or IND-enabling stage, and nearly 10 programs at proof-of-concept candidate (PCC) stage. Looking ahead to 2027, the company expects more than 10 programs in clinical trials, more than 10 at IND-approved or IND-enabling, and approximately 20 at PCC.
Proof of Concept (POC), Pharmaceuticals, Clinical Operations
Project
Research & Development, Machine Learning, Pharmaceuticals, Artificial Intelligence
XtalPi News & Media
XtalPi Holdings Announces 2026 Interim Results
SHENZHEN, China, Aug. 19, 2026 /PRNewswire/ -- Financial Highlights: In the first half of 2026, the Group recorded revenue of RMB393.6 million, compared with RMB517.1 million in the corresponding period of last year. The change was primarily attributable to the high base in the...XtalPi Holdings Limited to Announce 2026 Interim Results on August 19, 2026
SHENZHEN, China, Aug. 12, 2026 /PRNewswire/ -- XtalPi Holdings Limited ("XtalPi", or the "Company") (HKEX: 2228), an innovative research platform company powered by artificial intelligence (AI) and robotics, announced that it will report its interim results for the six months ended June...XtalPi Announces Strategic Partnership with a Leading Biopharma to Develop Oral Small Molecule Therapeutics for a GPCR Target
BOSTON and SHENZHEN, China, June 10, 2026 /PRNewswire/ -- XtalPi (2228.HK), a leading platform in artificial intelligence (AI) and robotics-driven drug discovery, today announced a strategic partnership with a prominent international biopharmaceutical company. The collaboration focuses on...XtalPi Receives Second Payment from DoveTree; First Oncology Asset Advances into IND-Enabling Studies
BOSTON, May 29, 2026 /PRNewswire/ -- XtalPi (2228.HK), an AI- and robotics- powered drug discovery platform, announced that its strategic collaboration with innovative biopharmaceutical company DoveTree Medicines Unus Inc. has achieved substantial progress, and that XtalPi has received...
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding XtalPi
Sign Up For FreeTo access detailed company insights
Founded in 2014, XtalPi is a biotech firm that uses artificial intelligence and computing to accelerate the development of new drugs. The firm uses algorithms to predict the crystalized form a drug will take. The data enables XtalPi to work with other pharmaceutical companies to develop new drugs and create new patents.XtalPi is located in China... Read More
